Optimi Health (TSE:OPTI) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Optimi Health has partnered with Psyence Biomed to supply GMP-certified psilocybin for clinical trials aimed at addressing unmet mental health needs in palliative care. This collaboration not only supports Psyence Biomed’s current Phase IIb trial but also prepares for future Phase III studies and potential commercialization. The exclusive agreement ensures that Psyence Biomed will use Optimi’s psilocybin extract for its drug development and FDA registration efforts.
For further insights into TSE:OPTI stock, check out TipRanks’ Stock Analysis page.